PMID- 31209700
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Linking)
VI  - 36
IP  - 8
DP  - 2019 Aug
TI  - Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in 
      Colorectal and Gastrointestinal Stromal Cancers.
PG  - 1986-1998
LID - 10.1007/s12325-019-01013-5 [doi]
AB  - INTRODUCTION: To assess the risk factors associated with regorafenib-related 
      adverse events (AEs) in metastatic colorectal cancer (mCRC) and gastrointestinal 
      stromal tumors (GIST). We also evaluated different measures of combatting AEs and 
      their success rate to aid physicians in early identification and management of 
      reported AEs. METHODS: A literature search was conducted through the electronic 
      databases PubMed, Embase, and Cochrane Central Register of Controlled Trials up 
      to May 2018 according to the pre-specified inclusion and exclusion criteria. 
      Pooled estimates with Pearson correlation were obtained with fixed or 
      random-effects models. RESULTS: From our analysis, it was evident that AEs were 
      more common in patients aged less than 65 years compared to those aged at least 
      65 years (71.3% vs. 27.6%, p = 0.001). A statistically significant correlation 
      was observed between the occurrence of AEs and a dose of 160 mg (r = 0.967; 
      p = 0.001) while no significant correlation was found at 120 mg and 80 mg. The 
      common measures used to manage AEs included lowering the regorafenib dose (41%), 
      intermittent drug withdrawal (66.7%), and complete drug withdrawal (19%). About 
      57% of patients recovered from AE after their initiating dose was lowered. 
      CONCLUSION: Regorafenib-associated AEs are more common at an initiating dose of 
      160 mg. Considering that the efficacy depends on the dosage, 120 mg might be a 
      better choice for mCRC and GIST patients; further studies are needed to validate 
      the results of our analysis. Further prompt identification and management of AEs 
      are required to help the patients continue with drug therapy.
FAU - Xie, Ganfeng
AU  - Xie G
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Gong, Yuzhu
AU  - Gong Y
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Wu, Shuang
AU  - Wu S
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Li, Chong
AU  - Li C
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Yu, Songtao
AU  - Yu S
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Wang, Zhe
AU  - Wang Z
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Chen, Jianfang
AU  - Chen J
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Zhao, Quanfeng
AU  - Zhao Q
AD  - Department of Pharmacy, Southwest Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, China.
FAU - Li, Jianjun
AU  - Li J
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China.
FAU - Liang, Houjie
AU  - Liang H
AD  - Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third 
      Military Medical University (Army Medical University), Chongqing, China. 
      lianghoujie@sina.com.
LA  - eng
SI  - figshare/10.6084/m9.figshare.8242427
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190617
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*therapy
MH  - Female
MH  - Gastrointestinal Stromal Tumors/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylurea Compounds/*adverse effects/*therapeutic use
MH  - Pyridines/*adverse effects/*therapeutic use
MH  - Risk Factors
OTO - NOTNLM
OT  - AEs
OT  - Adverse events
OT  - Correlation
OT  - Follow-up
OT  - Intermittent withdrawal
OT  - Lowering the dose
OT  - Regorafenib
EDAT- 2019/06/19 06:00
MHDA- 2020/05/26 06:00
CRDT- 2019/06/19 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/06/19 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
PHST- 2019/06/19 06:00 [entrez]
AID - 10.1007/s12325-019-01013-5 [pii]
AID - 10.1007/s12325-019-01013-5 [doi]
PST - ppublish
SO  - Adv Ther. 2019 Aug;36(8):1986-1998. doi: 10.1007/s12325-019-01013-5. Epub 2019 
      Jun 17.